Market volatility has led to compelling dividend opportunities, and Merck and Schlumberger offer great value at low PE ratios ...

Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...